Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Industry, Sector and Symbol
Industry Noncommercial research organizations
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Bionomics (OTCMKTS:BNOEF) Frequently Asked Questions
What is Bionomics' stock symbol?
Bionomics trades on the OTCMKTS under the ticker symbol "BNOEF."
What is the consensus analysts' recommendation for Bionomics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bionomics.
Has Bionomics been receiving favorable news coverage?
Headlines about BNOEF stock have been trending somewhat negative this week, InfoTrie reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bionomics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Bionomics.
Who are some of Bionomics' key competitors?
Some companies that are related to Bionomics include Stealth BioTherapeutics (MITO), Kromek Group (KMK), Nephros (NEPH), Cynata Therapeutics (CYYNF), Nephros (NEPHD), Sensus Healthcare (SRTS), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Pediapharm (PDP), OmniComm Systems (OMCM), Eyenovia (EYEN), Acorda Therapeutics (ACOR), MDxHealth (MXDHF), Mediwound (MDWD) and Trevena (TRVN).
What other stocks do shareholders of Bionomics own?
Who are Bionomics' key executives?
Bionomics' management team includes the folowing people:
- Dr. Errol B. De Souza, Exec. Chairman (Age 66)
- Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.
- Prof. Paul Rolan, Consultant Medical Officer of Clinical Neuroscience
How do I buy shares of Bionomics?
Shares of BNOEF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Bionomics' stock price today?
One share of BNOEF stock can currently be purchased for approximately $0.04.
How big of a company is Bionomics?
MarketBeat Community Rating for Bionomics (OTCMKTS BNOEF)
MarketBeat's community ratings are surveys of what our community members think about Bionomics and other stocks. Vote "Outperform" if you believe BNOEF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNOEF will underperform the S&P 500 over the long term. You may vote once every thirty days.
